Clinical trials: p53 Mutations
Li-Fraumeni Syndrome, Hereditary Cancer Syndromes
Biomarker Monitoring in TP53 Mutation Carriers
Purpose This study is an 'N-of-one' observational study focusing on individuals with a hereditary predisposition to cancer due to a genetic mutation in the TP53 gene.
- Conditions
- Li-Fraumeni Syndrome, Hereditary Cancer Syndromes, TP53 Gene Germline Mutation Carrier
- Trial name
- NCT02289326
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Scripps Health
Li-Fraumeni Syndrome, TP53 Gene Mutation
Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress
The purpose of this research study is to learn more about variants in the TP53 gene both associated with Li-Fraumeni Syndrome (LFS), a hereditary cancer risk condition, and TP53 variants found in the blood for other reasons (e.g.
- Conditions
- Li-Fraumeni Syndrome, TP53 Gene Mutation, Hereditary Cancer Syndrome, Clonal Hematopoiesis
- Trial name
- LiFT_UP (NCT04541654)
- Testing
- Data and Specimen Collection
- Where
- 3 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Dana-Farber Cancer Institute
Ovarian Cancer, Endometrial Cancer
Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 Mutation
This study is a Single-center, open, single-arm and non-randomized clinical trial in China. The aim of this study is to evaluate the efficacy, safety, and tolerability of Arsenic trioxide for injection in patients with recurrent…
- Trial name
- NCT04489706
- Testing
- Arsenic trioxide for injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
EGFR Gene Amplification, EGFR Gene Mutation
18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma
This phase II trial studies how well fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET) and osimertinib works in evaluating glucose utilization in patients with EGFR activated glioblastoma.
- Conditions
- EGFR Gene Amplification, EGFR Gene Mutation, Glioblastoma, Recurrent Glioblastoma
- Trial name
- NCT03732352
- Testing
- Fludeoxyglucose F-18, Osimertinib, Positron Emission Tomography
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Ovarian Cancer
A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
This is a study of the safety and efficacy of adavosertib in combination with paclitaxel plus carboplatin in the treatment of ovarian, fallopian tube, and primary peritoneal tumors with the P53 mutation.
- Trial name
- NCT01357161
- Testing
- adavosertib, paclitaxel, carboplatin
- Volunteers
- 136 people
- Sponsor
- Merck Sharp & Dohme LLC
Pediatric Cancer, Li-Fraumeni Syndrome
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
This prospective, single-arm, multi-center clinical trial aims to explore and evaluate the efficacy and safety of arsenic trioxide combined with chemotherapy for pediatric cancer with p53 mutation.
- Conditions
- Pediatric Cancer, Li-Fraumeni Syndrome, p53 Mutations
- Trial name
- NCT06088030
- Testing
- Arsenic trioxide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Yang Li
Education
Transition From Research to Disclosure in Human Genetics
The goal of this study is to design a means of providing research families, from diverse geographical locations, the chance to receive genetic testing after having been educated by video, and meetings or telephone conversations…
- Trial name
- NCT00505466
- Testing
- Genetic Counseling
- Where
- United States
- Volunteers
- 577 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Lymphadenectomy, Endometrial Cancer
SENTInel Node Mapping Versus Comprehensive Lymphadenectomy in p53-Mutated Endometrial Cancer: A Non-Inferiority Randomized Trial
This study evaluates surgical strategies for treating patients with FIGO 2023 stage I and II high-risk endometrial cancer (EC) exhibiting p53 mutations.
- Conditions
- Lymphadenectomy, Endometrial Cancer, Gene, p53, Sentinel Lymph Node Biopsy (SLNB)
- Trial name
- SENTIMETREP53 (NCT06900582)
- Testing
- Sentinel Lymph Node Mapping, Comprehensive pelvic and para-aortic lymphadenectomy
- Volunteers
- 374 people
- Sponsor
- University Hospital, Strasbourg, France
Colorectal Cancer, APC Gene Mutation
Patogenic Mutation in 5 Genes
This is a pathogenic mutation profile of colorectal patients specifically in 5 genes, i.e. APC, TP53, PIK3CA, KRAS, and MLH1. Single nucleotide variants identified were synchronized with patients' characteristics.
- Conditions
- Colorectal Cancer, APC Gene Mutation, TP53 Gene Mutation, PIK3CA Gene Mutation
- Trial name
- NCT04976439
- Testing
- co-occuring mutation
- Where
- Indonesia
- Volunteers
- 22 people
- Sponsor
- Dr Cipto Mangunkusumo General Hospital
P53 Mutation in Esophageal Cancer
ESCC Molecular Subtypes Based on Multidimensional Features of p53 and Their Clinical Significance
Collect 300 esophageal cancer tissue specimens, including cancer tissue and serum, from a biological sample bank. Collect clinical information on esophageal cancer, including gender, age, time of diagnosis, time of death…
- Trial name
- NCT07722819
- Testing
- No intervention
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Ling Zhiqiang
Diffuse Large B-Cell Lymphoma
First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma。The majority of refractory patients have PD-L1 expression due to P53 mutations, some of which account for about 10% of DLBCL.Our department has found that…
- Trial name
- NCT05280626
- Testing
- Sintilimab, Rituximab
- Volunteers
- 100 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Uterine Cancer, Endometrial Cancer
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
The purpose of this study is to determine the recommended Phase 2 dose of zanzalintinib when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer.
- Trial name
- NCT06795009
- Testing
- Zanzalintinib, Paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Washington University School of Medicine
Colorectal Cancer Metastatic, Colorectal Cancer Stage IV
The p53 Colorectal Cancer Trial
Single center, open labeled, phase 2 clinical trial, where patients with metastatic colorectal cancer are selected for treatment with dose dense Cyclophosphamide every second week based on TP53 mutation status; i.e.
- Conditions
- Colorectal Cancer Metastatic, Colorectal Cancer Stage IV, TP53 Gene Mutation
- Trial name
- NCT03149679
- Testing
- Cyclophosphamide
- Where
- Norway
- Volunteers
- 12 people
- Sponsor
- Haukeland University Hospital
P53 Mutation, Myeloid Malignancy
Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS
TP53 mutation is commonly associated with poor cancer patient prognosis yet no mutant p53 (mp53)-targeting regimen was clinically established.
- Conditions
- P53 Mutation, Myeloid Malignancy, MDS, Aml
- Trial name
- PANDA-T0 (NCT03855371)
- Testing
- Decitabine, Arsenic Trioxide
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Ruijin Hospital
Refractory Solid Tumors
Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation
This study is an open, prospective, single arm, multi center exploratory basket clinical study. 20 refractory solid tumors patients with rescuable p53 mutation will be enrolled, and the efficacy and safety of arsenic trioxide in…
- Trial name
- NCT04869475
- Testing
- Arsenic trioxide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Endometrial Carcinoma, P53 Mutation
A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer
This is an umbrella, two-arm, multi-stage, phase II trial. The purpose of the trial in the early stage cohort is to determine if EBRT improves disease free survival (defined as the time from random assignment to disease…
- Conditions
- Endometrial Carcinoma, P53 Mutation, Serous Carcinoma
- Trial name
- CAN-STAMP (NCT04159155)
- Testing
- External Beam Radiation, Niraparib, Vaginal high-dose rate brachytherapy
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- University Health Network, Toronto
Breast Cancer
Duct Endoscopy in Assessing Cellular Atypia in the Breast Duct Fluid of Women With a Genetic Risk for Breast Cancer
RATIONALE: Diagnostic procedures, such as breast duct endoscopy, may improve the ability to detect breast cancer earlier and plan more effective treatment.
- Trial name
- NCT00082979
- Testing
- cytogenetic analysis, proteomic profiling, cytology specimen collection procedure
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Ovarian Cancer, Breast Cancer
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
Background: All cells go through cycles which allow them to divide. In normal cells, checkpoint kinase 1 (Chk1) and checkpoint kinase 2 (Chk2) (CHEK 2 (Chk1/2) stop cell division at various points to allow any damage to…
- Conditions
- Ovarian Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT02203513
- Testing
- LY2606368
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- National Cancer Institute (NCI)
Arsenic Trioxide, p53 Mutations
Arsenic Trioxide for Structural p53 Mutations
TP53 is the most frequently mutated gene in cancer, but these mutations remain therapeutically non-actionable. Previous study reported arsenic trioxide could rescue structural p53 mutations, endowing p53 mutations with…
- Conditions
- Arsenic Trioxide, p53 Mutations, Refractory Cancer, Intractable Cancer
- Trial name
- NCT04695223
- Testing
- Arsenic Trioxide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Changzheng Hospital
Rectal Cancer
p53 and Response to Preoperative Radiotherapy for T2 and T3
Background: Meta-analyses of large randomized trials proved the superiority of preoperative short course radiation and surgery, as compared with surgery alone.
- Trial name
- PART1 (NCT02140723)
- Testing
- preoperative short course radiation
- Where
- Austria
- Volunteers
- 60 people
- Sponsor
- Medical University of Vienna